Elevance Health (ELV) Stock Forecast & Price Target

Compare

2,732 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ELV Analyst Ratings

Moderate Buy

12 Buy

5 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Elevance

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$367.81

▲(28.61%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $367.81 with a high forecast of $505.00 and a low forecast of $297.00. The average price target represents a 28.61% change from the last price of $285.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","549":"$549","359.25":"$359.3","422.5":"$422.5","485.75":"$485.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":505,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$505.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":367.81,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$367.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":297,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$297.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,359.25,422.5,485.75,549],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,404.1630769230769,412.56615384615384,420.96923076923076,429.3723076923077,437.7753846153846,446.17846153846153,454.58153846153846,462.9846153846154,471.3876923076923,479.79076923076923,488.19384615384615,496.5969230769231,{"y":505,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,393.61,391.46,389.31,387.15999999999997,385.01,382.86,380.71,378.56,376.41,374.26,372.11,369.96,{"y":367.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,395.76,388.1630769230769,380.56615384615384,372.96923076923076,365.3723076923077,357.7753846153846,350.17846153846153,342.58153846153846,334.9846153846154,327.3876923076923,319.79076923076923,312.19384615384615,304.5969230769231,{"y":297,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":526.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":523.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":548.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":504.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":365.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":393.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":430.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":406.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":375.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$505.00

Average Price Target$367.81

Lowest Price Target$297.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$315

Buy

10.15%

Upside

Upgraded

07/29/25

Elevance Health's overall stock score is primarily supported by strong financial performance and favorable valuation metrics. However, bearish technical analysis and challenges highlighted in the earnings call, such as cost pressures and membership declines, moderate the score. The company's ability to navigate these challenges will be crucial for its future performance.

A.J. RiceUBS

UBS

$435

Buy

52.11%

Upside

Reiterated

07/28/25

Elevance Health's 2026 EPS could land 'in low to mid 30s,' says UBSElevance Health's 2026 EPS could land 'in low to mid 30s,' says UBS

Michael HaRobert W. Baird

Robert W. Baird

$492→$297

Hold

3.85%

Upside

Reiterated

07/25/25

Elevance Health price target lowered to $297 from $492 at BairdElevance Health price target lowered to $297 from $492 at Baird

Lisa GillJ.P. Morgan

J.P. Morgan

$472→$384

Buy

34.28%

Upside

Reiterated

07/22/25

J.P. Morgan Remains a Buy on Elevance Health (ELV)JPMorgan analyst Lisa Gill lowered the price target on Elevance (NYSE: ELV) to $384.00 (from $472.00) while maintaining a Overweight rating.

Andrew Mok CFABarclays

Barclays

$358→$327

Buy

14.34%

Upside

Reiterated

07/22/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Veeva Systems (NYSE: VEEV) and Elevance Health (NYSE: ELV)

David ToungArgus Research

Argus Research

―

Hold

―

Downgraded

07/21/25

Elevance Health downgraded to Hold from Buy at ArgusElevance Health downgraded to Hold from Buy at Argus

Ben HendrixRBC Capital

RBC Capital

$478→$311

Buy

8.75%

Upside

Reiterated

07/21/25

RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)

Lance WilkesBernstein

Bernstein

$487→$445

Buy

55.61%

Upside

Reiterated

07/21/25

Bernstein Remains a Buy on Elevance Health (ELV)

Ryan LangstonTD Cowen

TD Cowen

$484→$330

Buy

15.39%

Upside

Reiterated

07/21/25

Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts

Erin WrightMorgan Stanley

Morgan Stanley

$316

Hold

10.50%

Upside

Reiterated

07/18/25

Elevance Health: Hold Rating Amid Elevated Utilization and Market Uncertainty

David WindleyJefferies

Jefferies

$488→$370

Buy

29.38%

Upside

Reiterated

07/18/25

Jefferies Remains a Buy on Elevance Health (ELV)

David S MacdonaldTruist Financial

Truist Financial

$440→$365

Buy

27.63%

Upside

Reiterated

07/18/25

Elevance Health price target lowered to $440 from $500 at TruistElevance Health price target lowered to $440 from $500 at Truist

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$485→$400

Buy

39.87%

Upside

Reiterated

07/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)

Kevin FischbeckBank of America Securities

Bank of America Securities

$350→$330

Hold

15.39%

Upside

Reiterated

07/18/25

Bank of America Securities Remains a Hold on Elevance Health (ELV)

Whit MayoLeerink Partners

Leerink Partners

$510→$310

Hold

8.40%

Upside

Downgraded

07/18/25

Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$315

Buy

10.15%

Upside

Upgraded

07/29/25

A.J. RiceUBS

UBS

$435

Buy

52.11%

Upside

Reiterated

07/28/25

Elevance Health's 2026 EPS could land 'in low to mid 30s,' says UBSElevance Health's 2026 EPS could land 'in low to mid 30s,' says UBS

Michael HaRobert W. Baird

Robert W. Baird

$492→$297

Hold

3.85%

Upside

Reiterated

07/25/25

Elevance Health price target lowered to $297 from $492 at BairdElevance Health price target lowered to $297 from $492 at Baird

Lisa GillJ.P. Morgan

J.P. Morgan

$472→$384

Buy

34.28%

Upside

Reiterated

07/22/25

J.P. Morgan Remains a Buy on Elevance Health (ELV)JPMorgan analyst Lisa Gill lowered the price target on Elevance (NYSE: ELV) to $384.00 (from $472.00) while maintaining a Overweight rating.

Andrew Mok CFABarclays

Barclays

$358→$327

Buy

14.34%

Upside

Reiterated

07/22/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Veeva Systems (NYSE: VEEV) and Elevance Health (NYSE: ELV)

David ToungArgus Research

Argus Research

―

Hold

―

Downgraded

07/21/25

Elevance Health downgraded to Hold from Buy at ArgusElevance Health downgraded to Hold from Buy at Argus

Ben HendrixRBC Capital

RBC Capital

$478→$311

Buy

8.75%

Upside

Reiterated

07/21/25

RBC Capital Reaffirms Their Buy Rating on Elevance Health (ELV)

Lance WilkesBernstein

Bernstein

$487→$445

Buy

55.61%

Upside

Reiterated

07/21/25

Bernstein Remains a Buy on Elevance Health (ELV)

Ryan LangstonTD Cowen

TD Cowen

$484→$330

Buy

15.39%

Upside

Reiterated

07/21/25

Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts

Erin WrightMorgan Stanley

Morgan Stanley

$316

Hold

10.50%

Upside

Reiterated

07/18/25

Elevance Health: Hold Rating Amid Elevated Utilization and Market Uncertainty

David WindleyJefferies

Jefferies

$488→$370

Buy

29.38%

Upside

Reiterated

07/18/25

Jefferies Remains a Buy on Elevance Health (ELV)

David S MacdonaldTruist Financial

Truist Financial

$440→$365

Buy

27.63%

Upside

Reiterated

07/18/25

Elevance Health price target lowered to $440 from $500 at TruistElevance Health price target lowered to $440 from $500 at Truist

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$485→$400

Buy

39.87%

Upside

Reiterated

07/18/25

Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)

Kevin FischbeckBank of America Securities

Bank of America Securities

$350→$330

Hold

15.39%

Upside

Reiterated

07/18/25

Bank of America Securities Remains a Hold on Elevance Health (ELV)

Whit MayoLeerink Partners

Leerink Partners

$510→$310

Hold

8.40%

Upside

Downgraded

07/18/25

Cautious Outlook for Elevance Health Amidst Earnings Growth Challenges and Sector Risks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month

xxx

Success Rate

13/24 ratings generated profit

Average Return

+0.65%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +0.65% per trade.

3 Months

xxx

Success Rate

23/40 ratings generated profit

Average Return

+0.37%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.50% of your transactions generating a profit, with an average return of +0.37% per trade.

1 Year

A.J. RiceUBS

Success Rate

20/29 ratings generated profit

Average Return

+15.57%

reiterated a buy rating 2 days ago

Copying A.J. Rice's trades and holding each position for 1 Year would result in 68.97% of your transactions generating a profit, with an average return of +15.57% per trade.

2 Years

xxx

Success Rate

24/29 ratings generated profit

Average Return

+38.81%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 82.76% of your transactions generating a profit, with an average return of +38.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ELV has received 37 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 367.81.

Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $5.66 with a range of $4.47 to $8.69. The previous quarter’s EPS was $8.84. ELV beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $49.26B with a range of $47.89B to $50.55B. The previous quarter’s sales results were $49.78B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?

Based on analyst ratings, Elevance Health’s 12-month average price target is 367.81.

What is ELV’s upside potential, based on the analysts’ average price target?

Elevance Health has 28.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ELV a Buy, Sell or Hold?

Elevance Health has a consensus rating of Moderate Buy which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.

What is Elevance Health’s price target?

The average price target for Elevance Health is 367.81. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $505.00 ,the lowest forecast is $297.00. The average price target represents 28.61% Increase from the current price of $285.98.

What do analysts say about Elevance Health?

Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of ELV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Elevance Health (ELV) Stock Forecast & Price Target

ELV Analyst Ratings

ELV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Elevance Health

ELV Analyst Recommendation Trends

ELV Financial Forecast

ELV Earnings Forecast

ELV Sales Forecast

ELV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts